JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
- Completion LockedNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 23, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03451851A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic...Janssen Research & Development, LLC · PsoriasisActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Jul 19, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04644770A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Dec 8, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT02908906A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal...Janssen Research & Development, LLC · NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 17, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03473743A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial CancerJanssen Research & Development, LLC · Urothelial CarcinomaActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Sep 30, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03492177A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActelion · Pulmonary Arterial HypertensionActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Mar 28, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT04662580ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerJanssen Research & Development, LLC · Metastatic Prostate CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell LungNot yet recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseJanssen Pharmaceutica N.V., Belgium · Alzheimer DiseaseActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Dec 22, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT03596645A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, UlcerativeActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Nov 21, 2023Actual
- Interventions
- Locked
- Completion LockedPhase 1NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · HealthyRecruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Feb 16, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06095102A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of...Janssen Research & Development, LLC · Plaque PsoriasisActive, not recruitingJNJLead
- Enrollment
- Locked
- Primary completion
- Jun 19, 2024Actual
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.